Acanthosis nigricans, insulin receptor antibody, and systemic lupus erythematosus are associated in the potentially lethal syndrome of type B insulin resistance. Hyperpigmentation has been reported rarely, while glucose intolerance is common in these patients. We report an adolescent girl with acanthosis nigricans, hyperpigmentation, insulin receptor antibody, and systemic lupus erythematosus without glucose intolerance. Insulin resistance may be mild or transient in some patients with type B insulin resistance. Resolution of skin lesions was noted during therapy of SLE, and was associated with disappearance of insulin receptor antibody.
Moller DE, Flier JSInsulin resistance-mechanisms, syndromes, and implications. N Engl J Med1991; 325: 938-948.
2.
Tuffanelli DLAcanthosis nigricans with lupoid hepatitis. JAMA1964; 189: 584-585.
3.
Brown J., Winkelmann RKAcanthosis nigricans: a study of 90 cases. Medicine1968; 47: 33-51.
4.
Wechsler B. et al. Lupus erythemateux aigu dissemine, diabete insulino-resistant et acanthosis nigricans. Ann Dermatol Venereol1981; 108: 23-30.
5.
Tsokos GC et al. Lupus nephritis and other autoimmune features in patients with diabetes mellitus due to autoantibody to insulin receptors. Ann Intern Med1985; 102: 176-181.
6.
Bella AF, Akintewe TA, Famuyiwa OOInsulin resistant diabetes mellitus associated with acanthosis nigricans and systemic lupus erythematosus in a Nigerian male. Afr JMedMed Sci1985; 14: 71-74.
7.
Kellett HA et al. Hyperandrogenism, insulin resistance, acanthosis nigricans, and systemic lupus erythematosus associated with insulin receptor antibodies . Metabolism1988; 37: 656—659.
8.
Rendon MI, Cruz PD, Sontheimer RDAcanthosis nigricans: a cutaneous marker of tissue resistance to insulin. J Am Acad Dermatol1989; 21: 461—469.
